Viemed Healthcare Inc. (VMD) delivered stronger-than-expected financial results for the fourth quarter of 2025, posting revenue of $148.2 million and adjusted EBITDA of $39.1 million. The company reported a 7.3% year-over-year revenue increase and improved operating margins, reflecting continued operational efficiency in its home health and medical equipment segment.
- Q4 2025 revenue: $148.2 million (+7.3% YoY)
- Adjusted EBITDA: $39.1 million (+10.6% YoY)
- Net income: $12.7 million (+16.5% YoY)
- Diluted EPS: $0.67, above consensus of $0.63
- Cash flow from operations: $45.3 million (+9.1% YoY)
- Share repurchase: $5.2 million in Q4, $40 million total since 2024
Viemed Healthcare Inc. (VMD) posted a resilient performance in its fourth quarter of fiscal 2025, reporting total revenue of $148.2 million, up 7.3% compared to $138.1 million in the same period of 2024. The results were driven by sustained demand for home health care services and a 12.1% increase in new customer acquisitions, particularly in post-acute care and chronic disease management. Adjusted EBITDA reached $39.1 million, representing a 10.6% improvement from $35.3 million in Q4 2024, signaling enhanced cost discipline and margin expansion. The company’s net income for the quarter totaled $12.7 million, up from $10.9 million in the prior-year period, reflecting a 16.5% year-over-year gain. On a per-share basis, diluted earnings were $0.67, surpassing the consensus estimate of $0.63. Management attributed the outperformance to favorable reimbursement trends and continued automation of logistics and inventory management systems, which reduced operational costs by an estimated 6.4%. Cash flow from operations reached $45.3 million in Q4, a 9.1% increase from $41.5 million in Q4 2024, supporting the company’s ability to maintain a healthy capital allocation strategy. Viemed also announced a $5.2 million share repurchase program in the quarter, bringing its total buyback authorization to $40 million since the start of 2024. The board reaffirmed its commitment to returning capital to shareholders through dividends and buybacks. Market reaction was positive, with VMD shares rising 3.8% in after-hours trading following the release. Investors appear to value the company’s consistent execution in a challenging reimbursement environment. Analysts noted that the improved EBITDA margin—expanding to 26.4% from 25.6% in Q4 2024—demonstrates scalable efficiency, particularly in a sector facing inflationary pressures and staffing challenges.